Aleph-4
| Clinical data | |
|---|---|
| Other names | ALEPH-4; DOT-4; 4-Isopropylthio-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-isopropylthioamphetamine; 4-iPrS-DMA |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | 12–20 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H23NO2S |
| Molar mass | 269.40 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Aleph-4, or ALEPH-4, also known as 4-isopropylthio-2,5-dimethoxyamphetamine, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families.[1] It is one of the Aleph series of compounds.[1] In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists Aleph-4's dose as 7 to 12 mg orally and its duration as 12 to 20 hours.[1] The effects of Aleph-4 have been reported to include closed-eye imagery, enhanced visual appreciation, emotional changes, and physical side effects and toxicity indications, among others.[1] One of the reports remarked that it was "one of the most profound and deep learning experiences" they had had.[1] However, Shulgin was unwilling to push the dose higher than 12 mg due to toxicity concerns.[1] The chemical synthesis of Aleph-4 has been described.[1] Aleph-4 was first described in the scientific literature by Shulgin, David E. Nichols, Peyton Jacob III, and other colleagues in 1978.[2] Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991.[1] The drug was encountered as a novel designer drug in Japan in 2009.[3][4]
See also
References
- ^ a b c d e f g h i j Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.https://erowid.org/library/books_online/pihkal/pihkal005.shtml
- ^ Braun U, Braun G, Jacob P, Nichols DE, Shulgin AT (1978). "Mescaline Analogs: Substitutions at the 4-Position" (PDF). In Barnett G, Trsic M, Willette RE (eds.). QuaSAR: Quantitative Structure Activity Relationships Of Analgesics, Narcotic Antagonists, And Hallucinogens (PDF). National Institute on Drug Abuse Research Monograph Series. Vol. 22. National Institute on Drug Abuse. pp. 27–37. PMID 101882.
- ^ Suzuki, J., Moriyasu, T., Nagashima, M., Kanai, C., Shimizu, M., Hamano, T., & Nagayama, T. (2010). Analysis of uncontrolled drugs purchased in fiscal year 2009. Ann RepTokyo Metrop Inst Public Health [Japanese: Tōkyō-to Kenkō Anzen Kenkyū Sentā Kenkyū Nenpō], 61, 163–172. https://isomerdesign.com/bitnest/external/TokyoMetr.Inst.PH/61.163
- ^ Uchiyama N, Miyazawa N, Kawamura M, Kikura-Hanajiri R, Goda Y (February 2010). "2008年度買い上げ違法ドラッグ製品から検出された新規流通デザイナードラッグの同定" [Analysis of newly distributed designer drugs detected in the products purchased in fiscal year 2008]. Yakugaku Zasshi (in Japanese). 130 (2): 263–70. doi:10.1248/yakushi.130.263. PMID 20118651.